EXCLUSIVE-EU reaches deals with Roche, Merck for supply of COVID-19 drugs - source
The EU executive agreed to the deal to source Roche's RoActemra and Merck's Rebif for supply to any 27 EU members states willing to buy them, the source who is familiar with the issue told Reuters. Roche and Merck were not immediately available for comment.
- Country:
- Belgium
The European Commission has reached agreements with pharmaceutical companies Roche and Merck KGaA to supply experimental drugs that can be used to treat COVID-19 patients, a commission source told Reuters on Wednesday. The EU executive agreed to the deal to source Roche's RoActemra and Merck's Rebif for supply to any 27 EU members states willing to buy them, the source who is familiar with the issue told Reuters. The person declined to be identified because of the sensitivity of the topic.
The source declined to disclose the terms of the deal. Roche and Merck were not immediately available for comment. A commission spokeswoman was also not immediately available for comment.
ALSO READ
-
Colombia Bets on Vaccine Manufacturing to Build Health Security and Cut Import Dependence
-
Colombia Gets €15 Million Boost to Build Vaccine Capacity and Cut Import Dependence
-
France Plans Housing Hub to Unlock European Funding and Technical Expertise
-
EU and EIB Launch Investor Pact to Help European Tech Firms Compete on Global Stage
-
EIB- UNDP €15 Million Partnership Backs Recovery for Communities in Crisis
Google News